Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Implication of Tumor Grade in Patients With Node-negative Breast Cancer Aged ≤ 50 Years With 21-gene Recurrence Scores of 11-25

NCT07093775 is registered in ClinicalTrials.gov with Gangnam Severance Hospital as lead sponsor.

NCT NCT07093775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07093775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Implication of Tumor Grade in Patients With Node-negative Breast Cancer Aged ≤ 50 Years With 21-gene Recurrence Scores of 11-25
Lead sponsor
Gangnam Severance Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
March 31, 2026
Enrollment
4,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, tumor grade